Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Cancer statistics, 2015

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2015 · 11.9K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

Marlo Blazer, Christina Wu, Richard M. Goldberg et al. · Annals of Surgical Oncology · 2014 · 250 citations · Full text

Medicine, Oncology, Chemotherapy +12

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Stacey Stein, Edward James, Yanhong Deng et al. · British Journal of Cancer · 2016 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17